JMP Securities analyst Jason Butler raised the firm’s price target on Argenx (ARGX) to $606 from $497 and keeps an Outperform rating on the shares. Argenx reported a strong quarter and highlighted the continued early success of chronic inflammatory demyelinating polyneuropathy VYVGART Hytrulo launch, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARGX: